BODi's Nutrition-First Pivot: Riding the GLP-1 Wave to a Turnaround

Beating Expectations, Again

BODi (The Beachbody Company) reported Q2 2026 results that came in above guidance on all three key metrics—revenue, net income, and adjusted EBITDA. Total revenue was $49.6 million, within the $46–51 million range, while adjusted EBITDA of $6.7 million exceeded the $3–6 million range. Net income of $1.4 million beat the high end of the range (loss of $3 million to breakeven). This marks the fourth consecutive quarter of positive operating income and net income, and the 11th consecutive quarter of positive adjusted EBITDA. As Mark Goldston put it, “across the board, revenue, net income and adjusted EBITDA, we either met or exceeded our own guidance again this quarter.” — Mark Goldston · 2026-08-10

The balance sheet also improved: cash of $32.4 million against total debt of $23.6 million yields a net cash position of $8.8 million. The company renegotiated its credit agreement with Tiger Finance, lowering covenant thresholds and increasing flexibility. This gives BODi room to invest while maintaining a cushion.

The GLP-1 Tailwind and Nutrition-First Strategy

The most significant strategic shift is the pivot to a nutrition-first, omnichannel model. Management is deliberately leaning into the GLP-1 boom. Carl Daikeler noted, “Our super food protein shake, Shakeology is seeing real demand from that same GLP-1 audience.” — Carl Daikeler · 2026-08-10 They're marketing Shakeology and 10-Minute BODi directly to GLP-1 users, highlighting that resistance training is crucial for those on weight-loss medications. The company's cost-to-acquire via nutrition is far lower than via fitness ads, so they've “inverted our media allocation toward nutrition advertising.” — Carl Daikeler · 2026-08-10 This is a clear reallocation of resources to a higher-margin, higher-demand channel.

Retail expansion is a key pillar. Shakeology is now in 131 Sprouts stores and just launched in 481 Vitamin Shoppe locations. KeHE and UNFI distribution deals are opening new doors. Even though planogram resets take 6–12 months, early reorders from Sprouts and the accelerated Vitamin Shoppe timing (ahead of fall) signal traction. The company is also launching P90X and Insanity energy drinks in a Southern California test market.

Shopify: Unlocking Conversion and Subscription Growth

The migration to Shopify, completed at the end of Q1, is already yielding visibility and agility. Shopify's audit identified sharp conversion improvements—better landing pages, faster checkout, and flexible bundles. Carl said, “Shopify has given us visibility to areas where we can make dramatic improvements in the sales funnel.” — Carl Daikeler · 2026-08-10 This is crucial as they prepare for Black Friday and the July 2027 fitness season. Amazon is also becoming a real channel: P90X supplements (priced $15–$40) launched last week, and Shakeology now has a 7-serve bag at $34.95, which is far more Amazon-friendly than the old $129–$169 30-serve bag.

The financials reflect the transition: gross margin was 72%, at the high end of guidance, with digital at 87.1% and nutrition at 46.7%. Operating expenses fell 32.1% YoY due to the MLM exit. Free cash flow was negative $5.7 million, attributed to inventory build for retail, but this is a deliberate investment.

So that combination, what we call the total solution is what has always driven this company's best results, and it's exactly what's fueling our direct-to-consumer expansion today.

Context: A Shared Theme Across the Market

BODi is not alone in chasing GLP-1 opportunities. Recent earnings calls across sectors show a weight loss obsession—from pharma to consumer goods to fitness. The company is also leveraging whey protein as a complementary product, aligning with broader protein trends. This consistency with a global theme amplifies the credibility of BODi's pivot. However, the near-term revenue decline (−22.4% YoY) is a result of the MLM wind-down, and management expects comparable YoY starting Q3 2026.

Ultimately, BODi is executing a disciplined turnaround: cutting legacy costs, building a nutrition-first retail and digital model, and riding a powerful demographic wave. The Q3 guidance ($44–48 million revenue, $3–6 million adjusted EBITDA) is cautious but consistent. With a net cash position, renegotiated covenants, and a clear growth roadmap, the company is positioning itself to return to growth in 2027.